Structure-based drug discovery of novel fused-pyrazolone carboxamide derivatives as potent and selective AXL inhibitors.

Authors:
Fang F; Dai Y; Wang H; Ji Y; Liang X and 12 more

Journal:
Acta Pharm Sin B

Publication Year: 2023

DOI:
10.1016/j.apsb.2023.10.002

PMCID:
PMC10692477

PMID:
38045061

View on PubMed View on PMC View Publisher
Journal Information

Full Title: Acta Pharm Sin B

Abbreviation: Acta Pharm Sin B

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Pharmacology & Pharmacy

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
ACAT1 deficiency in myeloid cells promotes glioblastoma progression by enhancing the accumulation o…
Wang M; Wang W; You S and 6 more (2023) - Transparency Score: 3/6
Acid-switchable nanoparticles induce self-adaptive aggregation for enhancing antitumor immunity of …
Sun X; Xu X; Wang J and 8 more (2023) - Transparency Score: 3/6
Activation of insulin-like growth factor-1 receptor (IGF-1R) promotes growth of colorectal cancer t…
Xie Q; Chu Y; Yuan W and 7 more (2023) - Transparency Score: 3/6
Activation of PXR causes drug interactions with Paxlovid in transgenic mice.
Lei S; Guo A; Lu J and 4 more (2023) - Transparency Score: 3/6
Adiponectin restores the obesity-induced impaired immunomodulatory function of mesenchymal stromal …
Pham DV; Nguyen TK; Nguyen BL and 4 more (2023) - Transparency Score: 3/6
View All Papers from This Journal
Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Conflicts of interest The authors declare no competing financial interest."

Evidence found in paper:

"This work was supported by the Natural Science Foundation of China for Innovation Research Group (81821005), the National Natural Science Foundation of China (21977106 and 82173834), the Collaborative Innovation Cluster Project of Shanghai Municipal Commission of Health and Family Planning (2020CXJQ02), the Shanghai Post-doctoral Excellence Program (2022231, China), the Shanghai Sail Program (22YF1460700, China), Lingang Laboratory (LG202103-02-07, China), Lingang Laboratory (LG-GG-202204-02, China)."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025